Marino Scherillo

Director of Cardiology & CCU SAN PIO Hospital
Benevento - 🇮🇹 Italy
Azienda Ospedaliera di Rilievo Nazionale e
di Alta Specializzazione DEA II⁰ Livello

[Marino Scherillo @pusallo]

🇮🇹 https://t.co/I1VU6FExEx
💟Interventional Cardiology and ICU
The Motto is
👉 " Doing good is possible if you do what you have to
and put yourself in what you do "

#Cardiology
#Cardiología
#Cardiologist
@_anmco
@SIC_CARDIOLOGIA
@sicigise
@ESCardioNews
@ehj_ed

[JACC Journals @JACCJournals]

In this network meta-analysis of 17 RCTs (13,751 pts), both #IVUS & #OCT guidance were superior to angiography alone for 📉 #MACE in complex coronary lesions (LM, bifurcations, CTOs, calcified, MVD). There was no difference between IVUS vs OCT 🫀 https://t.co/cg7UvSTbpT #JACCINT

[JACC Journals @JACCJournals]

📊 New meta-analysis in #JACC: GLP-1 RAs reduced CV death, MACE & HF risk across 99K+ patients.

✅ Consistent benefits across diabetes, obesity, CKD & HF
⚠️ ↑ GI & gallbladder events
🎯 Personalize therapy by patient profile

Read more in the new issue: https://t.co/7hWeZqRHhk

[Pritish Iyer @pritish_iyer]

Very cool - caffeine blocks adenosine receptors, which leads to faster heart rate, coronary vasoconstriction, and has historically thought to be a classic trigger for AFib episodes (thinking that caffeine amps up the heart as much as it amps up the mind).

By blocking adenosine, seems like caffeine could lengthen atrial cell refractory period, reduce ectopic triggers, and actually reduce the likelihood of AFib/flutter.

[Davide Capodanno @DFCapodanno]

Keeping up with this topic is really exhausting. Stop everything—here’s a new meta-analysis, this time in patients with myocardial infarction and preserved ejection fraction (≥50%). The first piece of news is that, after I don’t know how many years since the last cardiovascular one, it’s published in @NEJM (and yes, it’s very concise but stylish, of course). The second piece of news is that my post below, which was somewhat of a guess, turned out to be correct. Patients who have had a myocardial infarction and maintain a normal ejection fraction cannot expect any difference in mortality, reinfarction, or heart failure if they take a beta-blocker. If their ejection fraction is below 50%, however, benefits can be expected—and that is what I will do from now on. Until the next trial is published the day after tomorrow, of course. #AHA25
https://t.co/EEy72YqUaJ

[JAMA Cardiology @JAMACardio]

📊 Research Summary from @JAMA_current: Adults with #AFib who drank at least one cup of caffeinated coffee daily after successful cardioversion had a lower risk of recurrence than those who abstained from coffee and caffeine.

#AHA25 @AHAScience

https://t.co/uKGpjxpc9T

[Eric Topol @EricTopol]

Get this: Coffee suppressed atrial fibrillation!
Unexpected results for recurrence from a randomized trial in participants after cardioversion from AF
#AHA25 @JAMA_current ☕️ https://t.co/70dPI2R84C

[Felice Gragnano @FeliceGragnano]

📣 Clopidogrel outperforms aspirin as chronic monotherapy after PCI - better ischemic protection without increasing bleeding risk 👨‍⚕️💊

💥 P2Y12 inhibitors strike again! 💥

📌 SMART-CHOICE 3 is now online in @TheLancet 👉 https://t.co/BDC3cACUIl

@vlgmrc #Cardiology #ACC25

[American College of Cardiology @ACCinTouch]

RIVAWAR trial: Rivaroxaban was found to be as effective and safe as warfarin in resolving post #cvMI left ventricular thrombus at three months. #ACC25

Get full details here: https://t.co/aOVMadNEtt

[Davide Capodanno @DFCapodanno]

TAVI has become a key alternative to surgical aortic valve replacement, supported by strong evidence from randomized trials across all surgical risk levels. The balloon-expandable SAPIEN and self-expanding CoreValve/Evolut valves are established standards, with emerging valve technologies now undergoing direct comparisons against them. Here is a summary of such head-to-head comparisons.
https://t.co/T7nLi02dOJ

[The Heart @ZHeart11768530]

🔴Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing ASCVD Across the Risk Continuum #2023Review #openaccess

🔹https://t.co/3hNZsFgg6E
#CardioTwitter #CardioEd #Lipids #CVrisk #LDL

[The Heart @ZHeart11768530]

🔴Contemporary treatment options in HFpEF⤵️ #2024Review @ESC_Journals

🔹https://t.co/qUENes2j5d
#Diagnosis #Cardiology #ECG #EKG #Brugada #Syndrome #Table #Types #Morphology #ALiEM #Cardiology #FOAMed #MedEd #medstudent #paramedic #Cardiology #CardioEd

[The Heart @ZHeart11768530]

🔴2024 ACC/AHA Perioperative Guidelines⤵️
❤️10 take-home points #ACCAHAPerioperativeGuidelines

🔹https://t.co/Ng55zboMcn
#Cardiology #FOAMed #MedEd #medstudent #paramedic #Cardiology #CardioEd #medtwitter #meded #CardioTwitter #cardiotwiteros #MedX #cardiovascular

[Davide Capodanno @DFCapodanno]

Are all stents the same for high bleeding risk (HBR) patients? BioFreedom, Resolute Onyx, Synergy, and Xience are approved for HBR patients by both the European Commission and FDA. While Orsiro Mission has strong evidence for HBR use, it lacks specific HBR regulatory approval. Ultimaster and Supraflex Cruz are not specifically labeled for HBR but are approved for short DAPT durations. We wrote a brief article on the topic of stent selection for HBR patients.
https://t.co/5eiCffSxdq

[MIЯVΛƬ #IC ༄ ｡° @mirvatalasnag]

Image guided CHIP w IVL & Impella CP .. complète revascularisation of a NSTEMI in an octogenarian @KFAFHCards

What is the current evidence for PCI in this age group❓

SENIOR RITA @NEJM https://t.co/6aaVAixKl2 @VijayKunadian

FIRE 🔥 https://t.co/8a4e3YSmDq @SimoneBiscaglia

Let’s discuss this more @TCT_ME_ @crfheart @jjmt_heartrecov @ShockwaveIVL

[Felice Gragnano @FeliceGragnano]

Anti-inflammatory Strategies After Myocardial Infarction: the #TITIAN study 🔥
Now published in #EHJPharmacotherapy 💊

👉 https://t.co/6i6bvdigf8

@EditorEHJCVP 👨‍💼
@ESC_Journals 📚
@escardio 💟

@DFCapodanno @LaudaniClaudio @AGrecoMD @drgocchipinti @marcospagnolo21 #CardioEd

[EHJ Editor-in-Chief @ehj_ed]

"Non-traditional risk factors for atrial fibrillation: epidemiology, mechanisms, and strategies": explore how unexpected factors impact atrial fibrillation and innovative approaches to prevention and treatment.
https://t.co/iyd54eqje7
@ESCardio @ESC_Journals #AF

[Leandro Slipczuk @CardioMDPhD]

Phenotyping atherosclerotic plaque and perivascular adipose tissue: signalling pathways and clinical biomarkers in atherosclerosis @damini_dey @Piotr_JSlomka @imagingmedsci @danielbermanmd @DrAndrewLin @SmidtHeart @MonteHeart @NatRevCardiol #ACCimaging

https://t.co/T3RIUSqIiJ

[Felice Gragnano @FeliceGragnano]

Is the #Sidney4 the conclusive evidence for #ticagrelor monotherapy in acute coronary syndromes? 🧭
https://t.co/m42uGaQMOE

@TheLancet @vlgmrc
#Cardiology #CardioEd

[American College of Cardiology @ACCinTouch]

🗝️ Shared decision making for ICDs should highlight the survival benefit associated w/ them but also discuss possible complications associated w/ the device.

Read more key points on #epICD therapy for primary prevention in #HFrEF: https://t.co/YDlVBSolUi #JACCHF

@JACCJournals